The prognostic value of dopamine receptor occupancy by [123I]IBZM-SPECT in schizophrenic patients treated with quetiapine.
BACKGROUND
In the present study D2 receptor occupancy was investigated in quetiapine treated schizophrenic patients for the detection of a relationship between the scintigraphic pattern and clinical signs and symptoms.


METHODS
In 10 schizophrenic patients [123I]IBZM-SPECTs were performed during the introduction of quetiapine therapy (600-800 mg/day) and during a lower maintenance dose (200-400 mg/day). The patients' clinical follow-up was continued for 1 year. For the evaluation of SPECT images, visual interpretation was performed and striatum/occipital lobe (S/O) activity ratio was calculated.


RESULTS
The initial striatum/occipital ratio was significantly higher in patients with relapse compared to the others (1.86 +/- 0.17, 1.53 +/- 0.15, p < 0.01). The decreasing striatum/occipital ratio (increasing D2 receptor occupancy) on the 2nd SPECT was a predictive factor for the relapse.


CONCLUSIONS
D2 receptor occupancy and its changes during quetiapine therapy were related to the prognosis of the treatment efficacy.
Pávics
Lászlo
L
Department of Nuclear Medicine, University of Szeged, Hungary. pavicsl@ss10.numed.szote.u-szeged.hu
Szekeres
György
G
Ambrus
Edit
E
Kéri
Szabolcs
S
Kovács
Zoltán
Z
Argyelán
Miklós
M
Kanyó
Balázs
B
Csernay
László
L
Janka
Zoltán
Z
D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001549:Benzamides / Q000493:pharmacokinetics; D003342:Corpus Striatum / Q000000981:diagnostic imaging* / Q000187:drug effects / Q000378:metabolism*; D003987:Dibenzothiazepines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D011379:Prognosis; D011759:Pyrrolidines / Q000493:pharmacokinetics; D000069348:Quetiapine Fumarate; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D017448:Receptors, Dopamine D2 / Q000378:metabolism*; D012559:Schizophrenia / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000378:metabolism; D012720:Severity of Illness Index; D014018:Tissue Distribution; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods*; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D001549:Benzamides; D003987:Dibenzothiazepines; D011759:Pyrrolidines; D019275:Radiopharmaceuticals; D017448:Receptors, Dopamine D2; D000069348:Quetiapine Fumarate; C055743:3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide